This study is testing a new way to give a medicine called ATG (anti-thymocyte globulin) to help prevent acute GVHD (graft versus host disease) after an allogeneic stem cell transplant. GVHD is when the new immune cells from the donor attack your body. The study is for people aged 18-75 with acute leukemia, myelodysplastic syndrome, or myeloproliferative disorders who are receiving a stem cell transplant from a related or unrelated donor. You would receive prednisone and ATG infusions on specific days before your transplant. The main goal is to see how well this new ATG dosing prevents GVHD and relapse (when the cancer comes back) one year after transplant. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 56 participants. The study is testing a specific dosing platform of ATG combined with standard tacrolimus and mini methotrexate.

What's involved

You would be admitted to the hospital on Day -8 to receive prednisone, and then receive ATG infusions on Days -7, -6, -5, and -1 before your transplant.

Compensation

Not stated in the trial record.

Follow-up

The study will measure outcomes at one year post-transplant to see the rate of GRFS (GVHD and relapse-free survival).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.